New oral drug could replace steroids for severe colitis Flare-Ups
NCT ID NCT07502339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the oral medication upadacitinib can safely treat acute severe ulcerative colitis in hospitalized adults without using steroids. Fifty participants will take upadacitinib daily during their hospital stay and be monitored for up to a year. The goal is to see if this drug reduces the need for surgery or rescue treatments compared to past standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (oral JAK inhibitor)
What this could lead to
If successful, this could offer a steroid-free, oral treatment option for hospitalized patients with severe ulcerative colitis, potentially reducing the need for surgery or rescue therapy.
What could go wrong
This is a small, early-phase 4 study with only 50 participants and no placebo group. Results may not apply to all patients, and side effects of upadacitinib include infection risk and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UC - ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCSF Medical Center
San Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••